Visceral vs. subcutaneous fat
Body fat is not all the same. Two main depots:
- Subcutaneous adipose tissue (SAT), under the skin, distributed throughout body. Metabolically less active. Largely cosmetic concern.
- Visceral adipose tissue (VAT), surrounds internal organs in the abdomen. Metabolically active and inflammatory. Direct connection to liver via portal circulation.
Two people with identical BMIs can have very different metabolic risk profiles depending on visceral fat amount. The "skinny fat" phenomenon, normal weight with high visceral fat, predicts cardiovascular and metabolic disease similarly to obesity.
Why visceral fat is dangerous
VAT releases inflammatory cytokines (IL-6, TNF-α, leptin) directly into portal circulation, exposing the liver to chronic inflammation. This drives:
- Hepatic insulin resistance
- NAFLD/MASH progression
- Systemic inflammation
- Atherosclerosis acceleration
- Cardiovascular disease
VAT is also the source of much of the body's adipokine signaling that disrupts metabolic regulation system-wide.
GLP-1 effect on visceral fat
Imaging studies (CT, MRI, DEXA) in major trials:
- Visceral fat reduction 25-35% over 1-2 years on semaglutide
- Tirzepatide produces larger reductions (often 30-40%)
- Visceral fat reduction is proportionally larger than subcutaneous fat reduction
- Effect appears in first 3-6 months
- Liver fat (a related visceral fat) reduces 30-60%
Mechanism of preferential VAT loss
Why does VAT drop disproportionately?
- VAT is more metabolically active, higher lipolysis rate, mobilizes fat faster under negative energy balance
- VAT has higher receptor density for catecholamines, the fat-mobilizing hormones
- Reduced insulin and improved insulin sensitivity, high insulin promotes VAT storage; reducing insulin promotes VAT mobilization
- Reduced inflammation, feed-forward effect; less inflammation in VAT means fewer macrophages and immune cells protecting the depot
Why this matters clinically
The clinical implication: weight loss on GLP-1 therapy is qualitatively different from weight loss on simple caloric restriction or many other diet/medication approaches. Even patients who lose modest scale weight (10-15%) can have outsized improvement in:
- Insulin sensitivity
- Lipid profile (especially triglycerides)
- Liver enzymes
- Inflammatory markers
- Cardiovascular risk markers
Patients should not be discouraged by relatively modest scale weight loss if metabolic markers improve substantially, the visceral effect is happening even when total weight change is moderate.
How to measure
Visceral fat measurement options:
- DEXA with VAT estimation, most accessible
- CT or MRI imaging, most accurate, more expensive
- Waist circumference, proxy; men >40 inches, women >35 inches indicate elevated VAT
- Waist-to-hip ratio, proxy
- Lab markers, high triglycerides, low HDL, high fasting insulin all correlate with VAT
The clinical pearl: Visceral fat is where most of the metabolic damage from obesity actually lives. GLP-1 therapy targets it preferentially. This is part of why metabolic markers improve faster than scale weight changes, and why the scale doesn't tell the full story.
Bottom line
Visceral adipose tissue is the metabolically dangerous fat depot. GLP-1 therapy reduces it disproportionately to total weight loss, producing improvements in insulin sensitivity, inflammation, lipids, and cardiovascular risk that exceed what scale weight changes would predict. For patients evaluating their progress on therapy, lab markers and imaging often tell a more complete story than the scale alone.